| Followers | 1357 |
| Posts | 275127 |
| Boards Moderated | 53 |
| Alias Born | 12/07/2009 |
Friday, December 20, 2024 10:10:48 AM
David Weinstein, Chief Executive Officer of Renovaro, stated, “The potential for multi-cancer early detection screening and recurrence testing will be powered by AI chips that can process vast data sets. With this material step in acquiring the latest HPC capacity, Nebul and NVIDIA will help Renovaro in driving a vision towards a future where generic diagnostic scans for diseases can be done at any point of care with a single vial of blood, helping patients detect diseases early enough to get cured. This will help to massively reduce unnecessary treatments and address the soaring costs of care that are increasingly becoming a societal problem. We expect top-tier partnerships such as these will boost our technology’s visibility and potential, laying the foundation for our go-to-market strategy.”
Bullish
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Recent LNAI News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 09:30:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 09:00:31 PM
- Lunai Bioworks Unit Signs Preliminary Deal with Geneial on Rare Disease Data Collaboration • IH Market News • 04/15/2026 02:54:51 PM
- Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships • PR Newswire (US) • 04/15/2026 01:10:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:15:39 PM
- Lunai Bioworks unit secures defense collaboration for AI chemical threat platform • IH Market News • 04/07/2026 01:44:38 PM
- Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion • PR Newswire (US) • 04/07/2026 01:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/02/2026 09:01:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:35:01 PM
- Lunai Bioworks to acquire CNS drug delivery platform and Alzheimer’s assets for $20M • IH Market News • 03/26/2026 03:21:42 PM
- Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications • PR Newswire (US) • 03/26/2026 12:50:00 PM
- Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model • PR Newswire (US) • 03/19/2026 01:57:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 09:46:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:33:21 PM
- Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping • PR Newswire (US) • 02/19/2026 01:30:00 PM
- Lunai Bioworks Kicks Off AI-Driven Oncology Pilot to Analyze Phase 2 Colorectal Cancer Trial • IH Market News • 02/18/2026 02:05:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 08:16:26 PM
- Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC • PR Newswire (US) • 02/13/2026 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:15:48 PM
- Lunai Bioworks, Inc. Issues Letter to Shareholders • PR Newswire (US) • 02/09/2026 04:14:00 PM
- Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data • PR Newswire (US) • 02/09/2026 02:15:00 PM
- Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons • PR Newswire (US) • 01/27/2026 03:36:00 PM
- Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery • PR Newswire (US) • 01/26/2026 02:30:00 PM
- Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance • PR Newswire (US) • 12/18/2025 02:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 12/09/2025 10:43:08 PM
